It is estimated that
around 80% of innovator companies rely on external companion diagnostic
developers, mostly owing to the lack of the required in-house expertise. On the
other hand, there are numerous contract service providers, offering vast
portfolios of services for diagnostic test / assay development. Such companies
are known to possess extensive technical knowledge, and experience in working
with cutting-edge analytical tools and technologies, such as in situ
hybridization (ISH), immunohistochemistry (IHC), next generation sequencing
(NGS), polymerase chain reaction (PCR).
To order this 320+
page report, which features 120+ figures and 115+ tables, please visit this -
https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html
The USD 800+ million (by 2030) financial
opportunity within the companion diagnostics development services market has
been analysed across the following segments:
§
- Feasibility Studies
- Assay Development
- Analytical Validation
- Clinical Validation
§
§
§
§
§
§
§
§
§
The report features
inputs from eminent industry stakeholders, according to whom the development of
companion diagnostics is largely outsourced, owing to the exorbitant costs
associated with the setting-up of in-house expertise / capabilities. The report
includes detailed transcripts of discussions held with the following experts:
§
§
§
§
Table of Contents
1. Preface
4. Market Landscape
5. Company Profiles
6. Partnerships and Collaborations
7. Likely Partner Analysis
8. Company Competitiveness Analysis
9. Stakeholder Needs Analysis
10. Value Chain Analysis
11. Clinical Research on Cancer Biomarkers: Big Pharma
Perspective
12. Market Forecast And Opportunity Analysis
13. Executive Insights
14. Appendix 1: Tabulated Data
15. Appendix 2: List of Companies and Organizations
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
